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Abstract: Previously we had shown that ammonia stimulates nitric oxide (NO) synthesis in astrocytes
by increasing the uptake of the precursor amino acid, arginine via the heteromeric arginine/glutamine
transporter y+LAT2. Ammonia also increases the concentration in the brain of the endogenous
inhibitor of nitric oxide synthases (NOS), asymmetric dimethylarginine (ADMA), but distribution
of ADMA surplus between the intraastrocytic and extracellular compartments of the brain has not
been studied. Here we tested the hypothesis that ammonia modulates the distribution of ADMA
and its analog symmetric dimethylarginine (SDMA) between the two compartments of the brain by
competition with arginine for the y+LAT2 transporter. In extension of the hypothesis we analyzed
the ADMA/Arg interaction in endothelial cells forming the blood-brain barrier. We measured
by high-performance liquid chromatography (HPLC) and mass spectrometry (MS) technique the
concentration of arginine, ADMA and SDMA in cultured cortical astrocytes and in a rat brain
endothelial cell line (RBE-4) treated with ammonia and the effect of silencing the expression of a
gene coding y+LAT2. We also tested the expression of ADMA metabolism enzymes: protein arginine
methyltransferase (PRMT) and dimethylarginine dimethyl aminohydrolase (DDAH) and arginine
uptake to astrocytes. Treatment for 48 h with 5 mM ammonia led to an almost 50% reduction of ADMA
and SDMA concentration in both cell types, and the effect in astrocytes was substantially attenuated
by silencing of the Slc7a6 gene. Moreover, the y+LAT2-dependent component of ammonia-evoked
arginine uptake in astrocytes was reduced in the presence of ADMA in the medium. Our results
suggest that increased ADMA efflux mediated by upregulated y+LAT2 may be a mechanism by
which ammonia interferes with intra-astrocytic (and possibly intra-endothelial cell) ADMA content
and subsequently, NO synthesis in both cell types.
Keywords: astrocytes; rat brain endothelial cell line (RBE-4) cells; ammonia; nitric oxide; asymmetric
dimethylarginine (ADMA); symmetric dimethylarginine (SDMA); y+LAT2
1. Introduction
Hyperammonemia (HA) is defined as a clinical condition in which the ammonium ion
concentration in the blood and brain exceeds 130 and 500 µM respectively [1,2]. HA contributes
to progression of neurological disorders including acute and chronic forms of hepatic encephalopathy,
but also to congenital deficiencies of urea cycle enzymes, Reye’s syndrome, and several metabolic
or toxic encephalopathies [3]. One of the principle mechanisms by which ammonia damages the
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brain is oxidative/nitrosative stress (ONS) [4]. ONS is a result of enhanced production of reactive
oxygen species (ROS) followed by rapid reaction with NO to produce highly reactive nitrogen species
(RNS) [5]. Activation of NO synthesis by ammonia contributes to ONS in astrocytes [6–8], neurons [9],
and endothelial cells (e.g., rat brain endothelial cell line (RBE-4) cell line) alike [10]. While in neurons
induction of NO synthesis by ammonia is a straight consequence of over-activation of neuronal NMDA
receptors [11], in astrocytes it is prompted by increased uptake of the NO precursor arginine [12,13].
This process is facilitated by increased expression of the heteromeric glutamine/arginine transporter
y+LAT2 as demonstrated in ammonia treated astrocytes and RBE-4 cells [14,15], but also in the brain
cortex of HA rats [14].
Asymmetric dimethylarginine NG, NG-dimethyl-L-arginine (ADMA), is the most abundant
methylated arginine derivative in mammalian cells [16]. Unlike its analog NG, NG’-dimethyl-L-arginine
(symmetric dimethylarginine; SDMA), ADMA inhibits NO synthesis by competing with arginine at
the active site of nitric oxide synthase (NOS; EC 1.14.13.39) [17]. Furthermore, even relatively small
changes in intracellular L-Arginine/ADMA ratio can affect NOS activity in vivo and in vitro [18,19].
Metabolism of dimethylarginines are outlined on Scheme 1.
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Scheme 1. Asymmetric dimethylarginine (ADMA) and symmetric dimethylarginine (SDMA) are
formed by the methylation of arginine residues in a variety of proteins catalyzed by protein arginine
methyltransferases (PRMT). After proteolysis, arginine and its methylated forms are released as free
forms. ADMA elimination occurs primarily and specifically by its degradation by dimethylarginine
dimethyl aminohydrolases (DDAH-1 and -2), wherein only DDAH-1 is widely expressed in the
brain [20,21]. In turn, SDMA is extracted in urine.
ADMA can compete with arginine for two major cationic amino acid membrane transporters
belonging to two related protein families: cationic amino acid transporters (system y+) and the system
y+L, the latter represented by 4F2hc/y+LAT1 and 4F2hc/y+LAT2 [22]. HA is associated with increased
ADMA concentration in the brain tissue [23] and brain extracellular fluid [24], but the mechanisms
regulating distribution of the ADMA/SDMA surplus between the particular intra and extracellular
compartments have not be n studied. We hypothesized that treatment of astrocytes with ammonia
may elicit ADMA export from the cells by y+LAT2, a process likely to be facilitated by upregulation of
the carrier and competition by increased arginine uptak observed und r these conditions [13]. In this
study this hypothesis was tested in cultured astrocytes. Rat brain endothelial cells were considered as
one other brain compartment in which the mechanism operates.
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2. Results
2.1. The Effect of Ammonia and Slc7a6 Silencing on ADMA and SDMA Intra/Extracellular Concentration in
Cultured Astrocytes
The efficiency of Slc7a6 gene silencing procedure was tested first. A 48 h treatment with Slc7a6
siRNA reduced y+LAT2 protein level by ~50%. Sequences of siRNA complementary to y+LAT2 mRNA
completely abolished ammonia-induced increase of y+LAT2 expression (Figure 1).
Int. J. Mol. Sci. 2017, 18, 2308 3 of 13 
 
2. Results 
2.1. The Effec  of Ammonia and Slc7a6 Silencing on ADMA and SDMA Intra/Extracellular Concentration 
in Cultured Astrocytes 
The efficiency of Slc7a6 gene silencing procedure was tested first. A 48 h treatment with Slc7a6 
siRNA reduced y+LAT2 protein level by ~50%. Sequences of siRNA complementary to y+LAT2 
mRNA completely abolished ammonia-induced increase of y+LAT2 expression (Figure 1). 
 
Figure 1. The effect of silencing of the Slc7a6 gene on y+LAT2 protein level in astrocytes in relation to 
glyceraldehyde-3-phosphate dehydrogenase (GAPDH) protein level. Upper panel shows representative 
Western blots. Results are mean ± SD; n = 4, * p < 0.05 vs control; # p < 0.05 vs. ammonia. 
The effect of ammonia treatment and Slc7a6 gene silencing in primary cultured astrocytes 
obtained by high-performance liquid chromatography (HPLC) is shown in Table 1. Incubation with 
5 mM ammonia reduced both ADMA (by ~38%) and SDMA (by ~44%) without significantly changing 
Arg level. Silencing of Slc7a6 gene prevented ammonia-induced intracellular ADMA and SDMA 
reduction in astrocytes, indicating that y+LAT2 mediates transmembrane transport of 
dimethylarginines in these cells. 
Our hypothesis was supported by mass spectroscopic analysis of dimethylarginines in culture 
medium (Table 2). Ammonia increased extracellular ADMA and SDMA concentration by 15% and 
39% respectively. This effect was abolished by Slc7a6 gene silencing. Freshly prepared medium does 
not contain detectable amounts of dimethylarginines as was verified using the procedure included 
in Materials and Methods section. 
Table 1. Intracellular ADMA/SDMA/arginine (Arg) concentrations in ammonia-treated astrocytes 
and effect of Slc7a6 gene silencing. Results are mean ± SD; n = 8 (control; ammonia) n = 4 (Mock control; 
ammonia + y+LAT2 siRNA); * p < 0.05 vs. respective control; # p < 0.05 vs. ammonia. 
Intracellular 
Concentration Control Ammonia Mock Control 
Ammonia + 
y+LAT2 siRNA 
ADMA (µM) 7.3 ± 1.01 4.38 ± 1.80 * 6.91 ± 1.47 8.29 ± 0.84 # 
SDMA (µM) 5.82 ± 1.32 3.27 ± 1.18 * 5.29 ± 1.02 5.6 ± 1.31 
Arg (µM) 155.83 ± 50.4 176.33 ± 48.26 183.92 ± 37.83 155.35 ± 46.71 
Arg/ADMA 24.47 ± 4.16 41.84 ± 6.73 * 26.21 ± 4.05 21.11 ± 3.75 
ADMA/SDMA 1.23 ± 0.23 1.42 ± 0.37 1.26 ± 0.27 1.45 ± 0.33 
  
Figure 1. The effect of silencing of the Slc7a6 gene on y+LAT2 protein level in astrocytes in relation to
glyceraldehyde-3-phosphate dehydrogenase (GAPDH) protein level. Upper panel shows representative
Western blots. Results are mean ± SD; n = 4, * p < 0.05 vs. control; # p < 0.05 vs. ammonia.
The effect of ammonia treatment and Slc7a6 gene silencing in primary cultured astrocytes obtained
by high-performance liquid chromatography (HPLC) is shown in Table 1. Incubation with 5 mM
ammonia reduced both ADMA (by ~38%) and SDMA (by ~44%) without significantly changing Arg
level. Silencing of Slc7a6 gene prevented ammonia-induced intracellular ADMA and SDMA reduction
in astrocytes, indicating that y+LAT2 mediates transmembrane transport of dimethylarginines in
these c lls.
Our hy o hesis wa supported by mass spectroscopic a alysis of dimethylarginines in culture
medium (Table 2). Ammonia i creased extracellular ADMA and SDMA concentration by 15% and
39% respectively. This effect was abolished by Slc7a6 gene silencing. Freshly prepared medium does
not contain detectable amounts of dimethylarginines as was verified using the procedure included in
Materials and Methods section.
Table 1. Intracellular ADMA/SDMA/arginine (Arg) concentrations in ammonia-treated astrocytes and
effect of Slc7a6 gene silencing. Results are mean ± SD; n = 8 (control; ammonia) n = 4 (Mock control;
ammonia + y+LAT2 siRNA); * p < 0.05 vs. respective control; # p < 0.05 vs. ammonia.
Intracellular
Concentration Control Ammonia Mock Control
Ammonia +
y+LAT2 siRNA
ADMA (µM) 7.3 ± 1.01 4.38 1.80 6.91 ± 1.47 8.29 ± 0.84 #
SDMA (µ ) 5.82 ± 1.32 3.27 1.18 * 5.29 ± 1.02 5.6 ± 1.31
Arg (µM) 155.83 ± 50.4 176.33 ± 48.26 183.92 ± 37.83 155.35 ± 46.71
Arg/ADMA 24.47 ± 4.16 41.84 ± 6.73 * 26.21 ± 4.05 21.11 ± 3.75
ADMA/SDMA 1.23 ± 0.23 1.42 ± 0.37 1.26 ± 0.27 1.45 ± 0.33
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Table 2. ADMA/SDMA/Arg concentrations in cell culture medium following treatment with ammonia
and effect of silencing Slc7a6 gene silencing. Results are mean ± SD; n = 4; * p < 0.05 vs. control.
Extracellular
Concentration Control Ammonia Mock Control
Ammonia +
y+LAT2 siRNA
ADMA (µM) 0.365 ± 0.03 0.410 ± 0.04 * 0.358 ± 0.03 0.368 ± 0.05
SDMA (µM) 0.864 ± 0.24 1.378 ± 0.16 * 1.04 ± 0.09 1.189 ± 0.12
Arg (mM) 0.306 ± 0.12 0.312 ± 0.05 0.309 ± 0.04 0.301 ± 0.09
Arg/ADMA 864.24 ± 18.34 756.59 ± 9.66 * 872.33 ± 14.9 813.71 ± 12.28
ADMA/SDMA 0.44 ± 0.05 0.29 ± 0.06 0.36 ± 0.1 0.3 ± 0.04
To test if the effects of ammonia also comprise brain endothelial cells we measured intracellular
ADMA and SDMA concentration in rat brain endothelium cell line—RBE-4. Ammonia caused almost
50% reduction in ADMA and SDMA level in RBE-4 cells (Table 3).
The concentration of ADMA and SDMA measured in control untreated RBE-4 cells was markedly
higher than in astrocytes (Tables 1 and 3, respectively). Astrocytes were characterized by a higher
intracellular L-arginine/ADMA ratio (~25) than RBE-4 cells (~11). The central role of astrocytes in
ammonia neurotoxicity prompted us to focus further experiments within this study on astroglial cells.





ADMA (µM) 14.27 ± 2.23 8.29 ± 0.84 *
SDMA (µM) 4.29 ± 0.53 2.85 ± 0.31 *
Arg (µM) 134.39 ± 19.13 102.5 ± 11.18
Arg/ADMA 11.20 ± 3.05 14.33 ± 3.80
ADMA/SDMA 3.18 ± 0.25 2.97 ± 0.19
2.2. The Expression of ADMA-Metabolizing Enzymes
As mentioned in the Introduction ADMA and SDMA each, use different enzymes for their
synthesis and utilization. Identity of the patterns of ammonia-induced changes in ADMA and SDMA
(Section 2.1) suggested that events other than alterations in their metabolism (for instances transport)
are a more likely cause of reduction of intracellular ADMA concentration after ammonia treatment.
Nonetheless to test this inference, we measured the gene expression and protein level of ADMA
synthesizing enzyme PRMT-1 and a major utilization enzyme DDAH-1. Indeed, neither PRMT-1 nor
DDAH-1 was altered after ammonia treatment (Figures 2 and 3).
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Int. J. Mol. Sci. 2017, 18, 2308 5 of 13
Int. J. Mol. Sci. 2017, 18, 2308 5 of 13 
 
 
Figure 3. PRMT-1 and DDAH-1 protein level in primary astrocytes treated with 5 mM ammonia for 
48 h. Upper panel shows representative Western blots. 
2.3. The Nitrite/Nitrate Production in Cultured Astrocytes 
To determine whether observed depletion of intracellular ADMA and SDMA in ammonia 
treated cells may affect NO production we measured nitrites + nitrates (NOx) amount in the cultured 
medium. Ammonia enhanced by ~35% NOx concentration in cultured astrocytes medium. The effect 
was attenuated in cells in which y+LAT2 protein was down regulate (Figure 4). 
 
Figure 4. The effect of ammonia and Slc7a6 gene silencing on nitrite+nitrate (NOx) concentration in 
the medium derived from cultured astrocytes. Result are mean ± SD; n = 5, * p < 0.05 vs control,  
# p < 0.05 vs. ammonia. 
2.4. The Effect of ADMA on [3H]Arginine Uptake to Cultured Astrocytes 
ADMA may also act as inhibitor of arginine transport which inter alia is catalyzed by the y+L 
system. Incubation with 5 and 50 µM ADMA did not affect [3H]arginine uptake to astrocytes (Figure 5). 
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2.3. The Nitrite/Nitrate Production in Cultured Astrocytes
To determine whether observed depletion of intracellular ADMA and SDMA in ammonia treated
cells may affect NO production we measured nitrites + nitrates (NOx) amount in the cultured medium.
Ammonia enhanced by ~35% NOx concentration in cultured astrocytes medium. The effect was
attenuated in cells in which y+LAT2 protein was down regulate (Figure 4).
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Figure 4. The effect of ammonia and Slc7a6 gene silencing on nitrite+nitrate (NOx) concentration in the
medium derived from cultured astrocytes. Result are mean ± SD; n = 5, * p < 0.05 vs control, # p < 0.05
vs. ammonia.
2.4. The Effect of ADMA on [3H]Arginine Uptake to Cultured Astrocytes
ADMA may also act as inhibitor of arginine transport which inter alia is catalyzed by the y+L
system. Incubation with 5 and 50 µM ADMA did not affect [3H]arginine uptake to astrocytes (Figure 5).
Inhibition of [3H]arginine uptake was observed only at, relatively high, non-physiological ADMA
concentrations (0.5 and 1 mM) (Figure 5).
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3. Discussion
Excessive intracellular accumulation of reactive oxygen and nitrogen species (ROS and RNS,
respectively) resulting in ONS induction in the brain is a hallmark of ammonia neurotoxicity [25].
Accumulation of ROS/RNS has been successfully documented in hyperammonemic conditions in
situ, and in cultured astrocytes [8,26,27]. A distinct feature of the chain of reactions which translate
ammonia overexposure to NO synthesis in astrocytes is increased uptake of the NO precursor arginine,
a process facilitated by increased expression/activity of the heteromeric glutamine/arginine exchanger
y+LAT2 [13,15]. Accordingly, down-regulation of the y+LAT2 carrier has been documented as a
successful tool for the inhibition of NO synthesis and of the ensuing excessive S-nitrosylation in
astrocytes [15].
The asymmetric dimethylarginine (ADMA) serves as endogenous inhibitor of NOS, modulating
NO synthesis in various tissues [28–30]. Changes in the ADMA levels or L-arginine/ADMA ratio have
been noted in plasma of patients with acute liver failure [31], or with liver cirrhosis [32]. Increased
ADMA concentration in plasma and brain was also reported in animals with surgically or chemically
induced HE [33,34]. Recent studies in our laboratory demonstrated that ADMA accumulates in
the brain of rats with liver failure induced by thioacetamide [23,24]. However, the magnitude and
mechanistic details of interference by ADMA with NO synthesis under hyperammonaemic conditions
was not addressed by the previous studies and needs detailed elucidation.
A hypothesis has been put forward that ammonia-induced changes in ADMA content or
distribution in the brain may modulate NO synthesis not only by straightforward interaction with NOS,
but also by interfering with arginine availability for NO synthesis. This idea was prompted by data
indicating competition of ADMA and arginine for cell membrane transport sites. The present study
positively verified this hypothesis for astrocytes, the cells in which arginine overflow plays a critical role
in ammonia-induced NO synthesis (see Introduction). The principal findings favoring the hypothesis
are that (i) ammonia reduced intracellular ADMA concentration measured in astrocytes; (ii) silencing
of y+LAT2 coding gene was associated with an increase of ADMA in the cells and decrease of NO
production; (iii) the absence of the effects of ammonia on the protein levels of ADMA-metabolizing
enzymes and the reduction of intracellular level of SDMA, arginine derivative metabolized via distinct
enzymatic pathway (see Scheme 1) excludes classical, metabolic mechanism of ammonia action on
ADMA content in astrocytes.
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The present study extended our knowledge of described our previous study demonstrated that
ammonia-induced increase of NO synthesis is associated with increased [3H]arginine uptake via
upregulated in y+LAT2 [15]. The present study pointed to cellular ADMA depletion as one other
potential cause of ammonia-induced NO increase which is coupled to upregulation of y+LAT2. In
so far, this conclusion was derived from analysis of steady state ADMAi/ADMAe ratios. Clearly
this conclusion will have to be verified by comparing ADMA transport kinetics in y+LAT2-rich and
y+LAT2-deplete preparations.
Enhanced NO synthesis in astrocytes treated with ammonia is predominantly a result of inducible
nitric oxide (iNOS) induction [15]. The presence of sound evidence of y+LAT2-iNOS coupling in
ammonia-treated cultured astrocytes (15) did not a priori exclude the involvement endothelial nitric
oxide synthase (eNOS) in modulation of NO synthesis by ammonia [35]. However, in contrast to iNOS,
effective reduction of y+LAT2 transporter content did not affect eNOS mRNA expression, suggesting
the absence of y+LAT2–eNOS coupling in astrocytes [15]. At this point it is worth noting that ADMA
counteracts NO over-production caused by iNOS activation [36]. The possibility that ADMA inhibits
other NOS isoforms as well is worth a separate investigation.
The present data suggest that a mechanism similar to astrocytes holds for the RBE-4 cells, a rat
brain endothelial cell line mimicking endothelial cells forming the blood-brain barrier (BBB). Of note in
this context, the induction by ammonia of transcellular passage of low molecular BBB markers in RBE-4
cells is associated with increased y+LAT2 expression. Down the same valley, inflammatory factors
which are induced in hyperammonemic conditions, may activate iNOS in brain endothelial cells [37].
This could subsequently lead to y+LAT2-iNOS coupling. More detailed analysis of ADMA-mediated
regulation of NO synthesis in brain endothelial cells are under way.
Intracellularly formed dimethylarginines are exported to the extracellular fluid and plasma.
ADMA transport is mediated predominantly by cationic amino acid transporters (CATs) [18,37]. Recent
in vitro study on human embryonic kidney cells suggested the involvement in ADMA redistribution of
other transporters, such as organic cation transporter 2 and multidrug and toxin extrusion protein 1 [38].
Of note, in human embryonic kidney cells it is the y+LAT1 transporter which plays an important
role in depletion of intracellular ADMA, purportedly leading to eNOS uncoupling [39]. The present
study implicated, to our knowledge for the first time, functioning of the y+LAT2 transporter in the
same capacity in ammonia-affected astrocytes. Worth mentioning in this context are substantial
changes of transporter expression and activity in the whole brain of rats in HA associated with
thioacetamide-induced acute liver failure [14]. Since the mechanisms by which the endogenous
methylarginines are distributed between the extracellular and intracellular compartments are not well
characterized, existing evidence documented the involvement of y+ cation transporters [40] that may
have lower affinity but high capacity for ADMA [38]. However, our previous experiments documented
a lack of y+ system activation in ammonia-treated astrocytes, countering the involvement of y+ cation
transporters in the ammonia-induced enhancement of astrocytic NO synthesis [13].
Several groups have pointed out that elevation in ADMA (plasma and/or brain) concentration
observed in HE patients and animal models result from impaired ADMA metabolism [28,30,32].
However, our present work showed that in primary astrocytes, y+LAT2 activity may modulate
intra/extracellular ADMA distribution independently from activation of ADMA metabolism. This may
be concluded from both unchanged expression and protein level of PRMT-1 and DDAH-1 in ammonia
treated astrocytes and reduction of intracellular SDMA, a dimethylarginine, which is not metabolized
via the same enzymatic pathway as ADMA (see Scheme 1). The possibility that enzyme activities
pertinent to ADMA metabolism are altered by ammonia treatment can’t be excluded and definitely
deserves further examination. Nevertheless, neither elevated ADMA synthesis nor lowered ADMA
utilization in astrocytes can simply and directly explain the impact of Slc7a6 silencing on ADMA
intra/extracellular concentration. Therefore, we consider our observation of y+LAT2-dependent
modulation of ADMA distribution a valid addition to the mechanism irrespective of the effect on the
activities of enzymes. To support this statement, it’s worth noticing that decrease in DDAH activity
Int. J. Mol. Sci. 2017, 18, 2308 8 of 13
was observed in the brain cortex of rats with thioacetamide-induced liver failure but not in the brain
cortex of rats with hyperammonemia as have been demonstrated previously [21,41]. An additional
point related to DDAH activity needs clarification. Oxidative stress, one of the manifestations of
ammonia toxicity, was reported as a factor reducing DDAH activity in vitro. However even in the
cited study lowering of DDAH1/2 protein was also documented [42]. Therefore, the impact of the
decrease of DDAH activity on the response of NO synthesis to ammonia does not appear decisive.
The overall picture may be even more complex. For instance, depression of DDAH1 expression or
activity may be a result of polymorphisms of the DDAH1 gene [43,44]; reduced DDAH1 transcript
expression [21], or post-translational modifications such as oxidation of DDAH1 protein: these two
possibilities were not addressed in this study.
In conclusion, this study provides evidence that y+LAT2 transporter may control ADMA
elimination in a manner which offers protection against dysregulation of NO synthesis in
ammonia-treated astrocytes, and most likely in rat brain endothelial cells in vitro. The relevance
of the findings for understanding the role of changes in the ADMA distribution/content in the brain
affected by hyperammonemia remains to be documented. We are also fully aware that conclusions
from the present study need verification in the in vivo setting. Nonetheless, we considered classical
competition experiments with ADMA in the mmolar range as a prerequisite of addressing our
hypothesis. In so far, recent observation of increased extracellular ADMA content in the brain of rats
with thioacetamide-induced HE [24] appears to support the possibility of ADMA loss from astrocytes
and/or endothelial cells. Taken together this finding justifies further investigations on the role of
ADMA as a modulator of NO production in the pathogenesis of hyperammonemic encephalopathies
including HE.
4. Materials and Methods
4.1. Chemicals
ADMA, SDMA, ADMA-D6, ammonium chloride, were provided by the Sigma-Aldrich (St. Louis,
MO, USA); HPLC grade ethanol (EtOH), HPLC grade formic acid, gradient grade acetonitrile (ACN)
were purchased from Witko (Witko, Lodz, Poland). MQ Water was purified with Millipore (Millipore,
Bedford, MA, USA).
4.2. Cell Culture and Treatments
Primary astrocyte cultures were prepared from cortices of newborn Wistar rats using the method
described previously [13]. Briefly, cerebral cortex was isolated on ice, then passed through Nitex nylon
netting (pore size 80µm) into Dulbecco’s modified Eagle’s medium (DMEM; Gibco, Waltham, MA,
USA) containing 20% fetal bovine serum (Gibco). Cells were grown in 37 ◦C in humidified atmosphere
of 95% air and 5% CO2. Experiments were performed on 3-week astrocytes. RBE-4 cells were cultured
on the MEM/Ham’s F10 medium (Gibco) with addition of fibroblast growth factor-basic bFGF (Gibco).
Cells cultured for 4 days cells were used to further experiments. Astrocytes and RBE-4 cells were
treated with 5 mM ammonium chloride (“ammonia”) which was added into cell culture medium
for 48 h (1 M stock solutions of ammonium chloride were stored at −20 ◦C and added at indicated
concentration to culture medium).
4.3. Silencing of the Gene Coding for y+LAT2 Transporter
To down-regulate the y+LAT2 transporter, transfection with a mix of four types of siRNA duplexes,
consisting of 21 nucleotides was performed. Each type of siRNA was targeted to different gene region
to obtain the most effective gene silencing. Three-week astrocytes were washed with PBS solution,
trypsinized to detach cells and then seeded at a density of 0.7× 105 per well in 24-well culture plates in
0.4 mL of astrocytic growth medium. On the same day, cells were transfected with 5 nM of siRNA and
3 µL of HiPerFect transfection reagent (Qiagen Benelux BV, Venlo, the Netherlands)/per well, according
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to fast-forward protocol, designed for adherent cells and provided by manufacturer (Qiagen). The
mock control (transfection procedure without addition of siRNA) were used to indicate whether the
transfection process results in cytotoxicity or other non-specific effects. Cells were cultivated with the
transfection complexes under normal growth conditions for 48 h and then used for further experiments.
4.4. Dimethylarginines and Arginine Determination in Cell Homogenates and Culture Media
For determination of cellular ADMA, SDMA and arginine content, cells were washed with PBS
and homogenized by sonication in 5-sulfosalicylic acid and centrifuged at 12,000× g for 15 min.
Supernatant was neutralized and lyophilized. The lyophilizate was resolved in 40 mM acetate buffer
and loaded onto a column packed with AG50W-X8, previously conditioned with 20 mM acetate buffer.
Interfering compounds, i.e., proteins, acidic and neutral amino acids and weakly basic amines, were
rinsed off the cartridge with 3 mL of 20 mM acetate buffer (pH 5.5), followed by 4 mL of water, 2 mL
of 0.05 M ammonia, 8 mL of water, and 1 mL of methanol. Arg and its methylated metabolite were
eluted with 3 mL of 25% aqueous ammonia-methanol (1:1, v/v) [45].
Arginine, ADMA and SDMA concentration were analyzed using HPLC with fluorescence
detection after derivatization in a timed reaction with o-phthal aldehyde plus mercapto-ethanol, as
described earlier [23].
The levels of ADMA, SDMA and arginine in cell culture medium were analyzed using positive
mode electrospray LC–DMS–MS/MS. The deproteinized cell culture medium was mixed with
ADMA-D6 (IS) solution in EtOH (4 ng/mL). Solution was evaporated to dryness under nitrogen,
reconstituted with 45 µL of acetonitrile, and transferred to chromatographic vials. Samples were
analyzed using Waters Xevo TQ-S triple quadrupole mass spectrometer coupled with Waters Acquity
I-Class UPLC. A 3-min HPLC method was set up on Waters HILIC equipped with 1.7 µm 2.1 × 100 mm
column with thermostatic control at 70 ◦C. Mobile phase A was composed of 0.1% FA in ACN, mobile
phase B 0.1% FA in MQ. Linear gradient from 20% to 70% of phase B was used within 2.1 min with
the flow rate of 0.65 mL/min. Injection volume was 3 µL. MS detector worked in ESI ionization in
MRM mode. Separation was achieved by setting up MRM transitions that were highly specific for
each compound as it was previously reported in literature [46].
4.5. L-[3H]Arginine Uptake Assay
L-[3H]Arginine uptake was measured in control or y+LAT2 silenced astrocytes, treated or not
with 5 mM ammonium chloride. Cells were washed three times with Krebs buffer (Sigma-Aldrich,
St. Louis, MO, USA). Basal arginine concentration in the cells was adjusted to 100 µmolar concentration
by incubation in Krebs buffer containing 100 µM arginine for 10 min in 37 ◦C. Thereafter the solution
was replaced by incubation mixtures containing Krebs buffer with 0.1 µCi/mL l-[3H]Arginine (specific
radioactivity 37 MBq/mL; Hartmann Analytic) unlabeled arginine at 100 µmol/L and ADMA in the
concentrations: 5 µM, 50 µM, 0.5 mM, 1 mM, and the incubation was continued for 20 min. Cells were
then washed three times in ice-cold Krebs buffer, lysed in 0.5 mL 1M NaOH and protein content was
determined. The radioactivity of cell lysates was measured in a Wallac 1409 (Perkin–Elmer, Turku,
Finland) liquid scintillation counter.
4.6. Real-Time PCR Analysis
Total RNA from astrocytes was isolated using TRI Reagent (Sigma-Aldrich), and 1 µg of the RNA
was reverse transcribed using the high-capacity cDNA reverse transcriptase kit (Applied Biosystems,
Waltham, MA, USA). Real-time PCR was performed in 96-well plates with the ABI 7500 apparatus
(Applied Biosystems) using the Applied Biosystems Taqman probe assays: PRMT-1 (Rn 00821202),
DDAH-1 (Rn 00574200) β-actin (Rn 00667869). Each reaction contained 5 µL Taqman Universal PCR
Master mix in a total volume of 10 µL, and 1 µL cDNA was added to the reaction. The real-time
PCR reactions were performed for 10 min at 95 ◦C, followed by 40 cycles of 15 s at 95 ◦C, and 1 min
at 60 ◦C. The results of the analysis were calculated in relation to the β-actin product, and results
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were presented according to an equation (2−∆∆Ct) that gives the amount of target, normalized to an
endogenous reference, and relative to a calibrator. Ct is the threshold cycle for target amplification [47].
4.7. Protein Isolation and Western Blot Analysis
Astrocytes were washed in PBS and homogenized by sonication in RIPA Lysis and Extraction
buffer (Sigma-Aldrich) containing Protease Inhibitor Cocktail (concentration 1:200, Sigma-Aldrich)
phosphatase inhibitor cocktail (concentration 1:100, Sigma-Aldrich) andf 50 µM sodium fluoride 0.5 M
(Fluka, Sigma-Aldrich) and then centrifuged for 10 min at 10 000× g and 4◦C. The supernatants
was transferred to a new Eppendorf tube. Equal amounts of protein (30 µg) were separated on 10%
SDS-polyacrylamide gel and transferred onto nitrocellulose membrane. Membranes were blocked with
5% nonfat dry milk in TBS-Tween buffer (50 mM Tris; 150 mM NaCl; 0.1% Tween 20). The membranes
were than incubated over-night with anti-y+LAT2 antibody (1:1000, Sigma-Aldrich), anti-PRMT-1
(1:1000 Cell Signaling, Danvers, MO, USA) and anti-DDAH-1 (1:250 Santa Cruz Biotechnologies,
Dallas, TX, USA), followed by 1 h incubation with HRP-conjugated-secondary IgG antibodies (1:5000,
Sigma-Aldrich) for detection by Clarity Western ECL Substrate (Bio-Rad Laboratories, Hercules,
CA, USA). The first antibody was stripped off with 0.1 M glycine, pH 2.9, and second incubation
was performed with an antibody against Glyceraldehyde 3-phosphate dehydrogenase (GAPDH) 1 h
incubation at 20–22 ◦C (1:7500, HRP-60004, ProteinTech, Manchester, UK). The chemiluminescent
signal acquisition and densitometry analysis were conducted using the G-Box system (SynGene,
Bengaluru, India) and GeneTools software (SynGene).
4.8. Determination of Nitric Oxide (NO) Concentration
As an index of NO production, nitrites amount in the cultured medium were measured together
with nitrates (nitrite + nitrate = NOx) using Nitrate/Nitrite Colorimetric Assay Kit (Cayman Chemical
Company, Ann Arbor, MI, USA), according to the manufacturer’s protocols.
4.9. Protein Determination
Total protein concentration was determined by the Lowry method using Modified Lowry Protein
Assay Reagent (Pierce, Thermo Fisher, Waltham, MA, USA).
4.10. Statistical Analysis
Biochemical parameters were analyzed by one-way ANOVA with a post hoc Dunnet’s test. All
analyses were performed using 5.0 Graph Pad software (San Diego, California, USA). Values were
expressed as mean ± S.D.; p < 0.05 or less was considered statistically significant.
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